Reportstack Announces the Publication of its Research Report - Global RNAi Drug Delivery Market 2014-2018. The following companies are the key players in Global RNAi Drug Delivery Market: Alnylam Pharmaceuticals Inc., Isis Pharmaceuticals, Inc.,Merck & Co. Inc., and Tekmira Pharmaceuticals Corp. “Major advances in RNAi drug delivery are aimed at developing better delivery agents with excellent efficacy and the ability to target specific cells. For example, Bio-Path Holdings Inc. developed systemic delivery of antisense, small interfering RNA, and hydrophobic small molecules for treatment of various diseases using its neutral lipid drug delivery technology (neutral liposome). Similarly, Inovio's skin electroporation technology was used for the successful delivery of small interfering RNA molecules to skin in animal studies. Thus, technological innovations would further contribute to the growth of the Global RNAi Drug Delivery market.”
According to the report, one of the major drivers in this market is the increase in RNA therapeutic development. Therapeutic benefits greatly depend on the efficiency of the RNA delivery to specific diseased cells. This factor is the key to the development of RNAi drug delivery technologies and the market associated with it.
Further, the report states that one of the major challenges in this market is the targeted delivery of RNA therapeutic molecules. During in vivo drug testing procedures, many companies engaged in developing RNA therapeutics found it difficult to deliver the RNA molecules to specific tissues to bring about a therapeutic effect.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit http://www.reportstack.com/product/150194/global-rnai-drug-delivery-market-2014-2018.html
According to the report, one of the major drivers in this market is the increase in RNA therapeutic development. Therapeutic benefits greatly depend on the efficiency of the RNA delivery to specific diseased cells. This factor is the key to the development of RNAi drug delivery technologies and the market associated with it.
Further, the report states that one of the major challenges in this market is the targeted delivery of RNA therapeutic molecules. During in vivo drug testing procedures, many companies engaged in developing RNA therapeutics found it difficult to deliver the RNA molecules to specific tissues to bring about a therapeutic effect.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit http://www.reportstack.com/product/150194/global-rnai-drug-delivery-market-2014-2018.html
No comments:
Post a Comment